[email protected]

+971561741745

Professional Summary

Mohamed Mostafa

A pharmaceutical management and marketing leader with 21 years of extensive and diversified experience driving enduring change and delivering remarkable success in diverse markets
and different disease area like Rare Diseases, Oncology and Hematology Supportive Care, Gastroenterology and Respiratory across a broad range of pharmaceutical brands in different life cycles and different therapy area including both primary and specialty care brands across Middle East, Turkey and Africa.

Professional Experience:

Middle East Commercial Consultant Techdow Pharma (Biosimilars)
Dubai July 2018 – Present
Key Responsibilities:
·         MENA region business model setup, access strategy & priority markets.
·         Appoint partners and commercial network in MENA region.
·         Techdow product access to MENA region tender and retail market.
General Manager Kyowa Kirin Pharmaceuticals GCC (Rare Diseases &Oncology)
Dubai August 2017 – June 2018
Key Accomplishments:
·         Set up Kyowa Kirin Regional Office in Middle East – FZ LLC.
·         Appointment of Kyowa Kirin Distributors network in GCC.
·         Recruitment of the senior leadership team (Medical, BU Head).
·         Repatriation of Amgen supportive care portfolio (Neupogen, Neulastim and OBI) in GCC, business size 20 Million USD, Drafting Transfer Service Agreement with Amgen, Distributors assessment, termination and appointing new partners, Preparing the markets for new Launches, Managing price references during Marketing Authorization Transfers, Managing inventory and bridging stocks and supply chain complexity.
·         Tender management in GCC, taking decisions on tender participation, pricing strategy and tenders control.
·         Pricing Strategy for Neupogen, Neulastim and OBI in GCC for 5 years.
Country lead Saudi Arabia Concordia international (Former Amdi Pharm Mercury UK)
Saudi Arabia, April 2015 – July 2017

Key Accomplishments:
·         Outstanding results for Concordia which translated into +50% EBIT overachievement in 2015 and 2016 through different and smart strategies,

1.       Freight cost smart control which resulted in 4% cost saving.

2.       FOC control for the strategic products which improved the EBIT by 5%.

3.       Portfolio prioritization and focusing on high profit margin products which lead to an EBIT increase by 14%.

4.       Head count synergies which resulted in 4%

5.       Bad debts recovery– Over 3 Million USD.

·         Secure Concordia business continuity in Saudi market by:

1.       Appointment of a non-exclusive distributor (one of the top 5 distributors in Saudi market) resulted in:

(a)    Improvement in the account receivables from 180 days in average to 90 days.

(b)    Strategic items availability and avoiding the historical stock rupture by building a strategic stock which results in smooth and uninterrupted in-market sales.

2.       3 million USD bad debts recovery from the distributors without using the court option.

·         Over achieving 2016 budgeted revenues by 20% through:

1.       30% GR in the in-market sales for key strategic products in the private market.

2.       Excellent tender management which resulted in 150% GR of the awarded items value.

Gastro Franchise Head Takeda Pharmaceuticals META January 2014 – March 2015 – Middle East, Turkey and Africa Key Accomplishments:

·         Increase Takeda PPI MS in Proton Pump Inhibitor (PPI) segment by 3% in Year 1 after launching Takeda 2nd PPI to the market in UAE through a very successful co-positioning strategy resulted in increase on Takeda PPI MS to be 21%

Head of Marketing Takeda Pharmaceuticals ELIP
May 2013 – December 2013 – Egypt, Levant, Iran and Pakistan

Key Accomplishments:
·         Increase EBIT by 7% through restructuring the sales force (lines up) to create more synergies and accommodate more products.

·         Revenue growth by 2% through in-license of the GI products that fit with Takeda PPI portfolio.

Product Manager Takeda Pharmaceuticals. March 2011 – April 2013 – Gulf, Levant and Iran Key Accomplishments:

·         Daxas successful launch in Lebanon 2011, UAE 2012 achieving 6% & 3% respectively MS in year 1 in COPD defined market.

·         Omnaris Successful launch in UAE 2012 and achieving 10% MS in year 1.

Product Manager Takeda Pharmaceuticals Egypt
November 2007 – February 2011 – Egypt

Key Accomplishments:
·         Increase Controloc (Takeda PPI) by 4 points MS to maintain its leading position in PPI market by 17.8% MS through smart marketing strategies in a very crowded and highly genericized market.

·         Alvesco launch in Egypt 2009 and achieve 14% in the inhaled steroid segment in year 1.

Institution Executive AstraZeneca KSA
February 2001- October 2007, KSA Gastro & Respiratory team

Key Accomplishments:
·         Formulary enlisting of Nexium in Saudi Aramco, Armed Forces Hospitals.

Medical Representative Janssen Cilag KSA
Jan 1998 –Jan 2001, KSA

Gastro & Anti-mycotic line private sector

Medical Representative Ferring Pharmaceuticals Egypt
Jan 1997 – Dec 1997, Egypt

Education:
1996 Bachelor Degree of Pharmacy, Cairo University – Egypt, Grade: Good